Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Publ. Version/Full Text
DOI
PMC
 |
Open Access Hybrid |
|
as soon as is submitted to ZB.
A multiscale approach to lipid nanoparticle engineering from molecular structure to in vivo performance.
J. Control. Release 394:114911 (2026)
The 2023 Nobel Prize in Physiology or Medicine recognized the discovery of base modifications that enabled effective mRNA vaccine development. Highlighting this, the former president of the Controlled Release Society, Twan Lammers, at the society's 2024 annual meeting, noted that it may soon be time for this recognition to extend to breakthroughs in drug delivery systems. Indeed, it was modern delivery technologies that unlocked the potential of RNA-based medicines, with lipid nanoparticles (LNPs) enabling their clinical translation less than a decade ago. While LNPs have proven essential for many nucleic acid delivery applications, their rational design remains challenged by complex lipid-RNA interactions, biological barriers, and the dynamic nano-bio interface. In this review, we highlight state-of-the-art strategies in LNP development, including computationally guided design, high-throughput screening, and insights into how protein corona formation shapes in vivo performance.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Library Screening ; Molecular Barcoding ; Molecular Dynamics Simulations ; Protein Corona; Messenger-rna Delivery; Protein Corona; Surface; Optimization; Discovery; Equation; Design; Serum; Lung; Saft
ISSN (print) / ISBN
0168-3659
e-ISSN
1873-4995
Journal
Journal of Controlled Release
Quellenangaben
Volume: 394,
Article Number: 114911
Publisher
Elsevier
Publishing Place
Radarweg 29, 1043 Nx Amsterdam, Netherlands
Reviewing status
Peer reviewed
Institute(s)
Institute for Intelligent Biotechnologies (IBIO)